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ABSTRACT

Objectives The primary objective was to compare the
efficacy of enteral potassium replacement (EPR) and
intravenous potassium replacement (IVPR) as first-line
therapy. Secondary objectives included comparison of
adverse effects and number of doses required to resolve the
episode of hypokalaemia.
Trial design The EIPS trial is designed as a randomised,
equivalence trial between two treatment arms.
Study setting The study was conducted at the paediatric
cardiac intensive care unit (PCICU) at Aga Khan University
Hospital, Karachi.
Participants 41 patients (aged 1 month to 15 years) who
were admitted to PCICU post cardiac surgery were recruited
(23 IVPR arm and 18 EPR arm).
Intervention Intervention arms were block randomised on
alternate weeks for IVPR and EPR.
Outcome measure Change in serum potassium levels
in (mmol/L) and percentage change after each event of
potassium replacement by the intravenous or enteral route.
Results Both groups (41 patients) had similar baseline
characteristics. Mean age was 4.7 (SD±4) years while
the most common surgical procedure was ventricular
septal defect repair (12 patients, 29.3%). No mortality was
observed in either arm. Four episodes of vomiting and one
arrhythmia were seen in the EPR group. After adjusting for
age, potassium level at the beginning of the episode, average
urine output, inotropic score and diuretic dose, it was found
that there was no statistically significant difference in change
in potassium levels after EPR and IVPR: 0.86 mmol/L (±0.8)
and 0.82 mmol/L (±0.7) respectively (p=0.86, 95% CI −0.08
to 1.10), or percentage change in potassium level after
enteral and intravenous replacement: 26% (±30) and 24%
(±20) (95% CI −3.42 to 4.03, p=0.87).
Conclusion EPR may be an equally efficacious alternative
first-line therapy in treating hypokalaemia after surgery in
selective patients with congenital heart disease.
Ethics and dissemination This study has been approved
by Ethics Review Committee at AKU.
Trial registration number NCT02015962.

Strengths and limitations of this study
►► EIPS is the first prospective randomised equivalence

trial comparing the routes (enteral vs intravenous)
for potassium replacement in paediatric patients in
intensive care post cardiac surgery.
►► A retrospective review has previously shown
comparable efficacy between the two routes.
►► Research from this trial will lead the way for further
research in this field, possibly bringing about a
change in the management of hypokalaemia in
patients after surgery and subsequently lower
complications and morbidity associated with
intravenous potassium replacement.
►► EIPS is not a blinded study, which may lead to a
procedure bias. Blinding could not be carried out in
this trial owing to different routes of administration of
the same supplementation (enteral vs intravenous)
and different time intervals for checking serum levels
in each arm (1 hour after intravenous replacement
and 2 hour after enteral replacement).
►► Confounding factors, such as concomitant use of
diuretics and inotropic agents during the episode,
were identified and adjusted in the analysis.

INTRODUCTION
Hypokalaemia is a frequently encountered
electrolyte abnormality in the daily clinical
practice of the paediatric cardiac intensive
care unit (PCICU). In the postoperative
period, activation of the renin–angiotensin–
aldosterone system, enhanced sympathetic
tone and use of potassium-wasting diuretics
for positive fluid balance have led to
increased occurrence of severe hypokalaemia
and its consequences.1 Hypokalaemia is a
strong independent predictor of mortality
in patients with heart failure.2–4 Potassium
replacement remains the cornerstone therapy
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for hypokalaemia. There is mounting evidence that the
serum potassium level should be maintained between
3.5 and 4.5 mmol/L5 or even higher in the setting of
acute cardiac injury.6 7 Thus it is highly desirable to avoid
hypokalaemia by close monitoring and subsequent potassium replacement.
Although intravenous potassium replacement (IVPR)
in hypokalaemia is the preferred route in most intensive care settings, it is associated with known safety risks.
IVPR can lead to arrhythmias, cardiac arrest and death if
administered inappropriately.2 8 9 Given these risks, IVPR
is considered a ‘high-alert medication’ by the Institute
of Safe Medication practice.10 11 The need to maintain
and frequently access a central line for administration of
higher concentrations of potassium can lead to serious
central line infections. Inability to use high-concentration potassium through peripheral lines may lead to
administration of a larger volume of fluid for the delivery
of the desired dose of potassium, thus disturbing the
fluid balance in these patients. This may be detrimental
in cardiac patients after surgery in whom a negative fluid
balance is optimal. Given all the above mentioned issues
with IVPR, enteral potassium replacement (EPR), with
its equal or superior safety profile, may be a better alternative to IVPR. A retrospective review showed that the
efficacy of EPR was comparable to IVPR in paediatric
patients after surgery for congenital heart disease.9
We sought to explore this comparison between EPR
and IVPR in a randomised equivalence trial to determine
if EPR can be used as an alternative to IVPR.
This trial was registered at ClinicalTrials.gov (registration number: NCT02015962). This manuscript describes
the results of the trial. Consort checklist of the trial is
also included as supplementary file. Details of the trial
protocol and design have been previously published.12

randomised, non-blinded, equivalence trial with two
arms. Arm A (IVPR) received intravenous potassium
replacement while Arm B (EPR) received enteral potassium replacement as a treatment for hypokalaemia.
Intervention arms were block randomised in alternate
weeks for IVPR and EPR for the sake of convenience
and to minimise error in drug delivery.
METHODS
Definitions used for the study
Hypokalaemia
Hypokalaemia was defined
<4.4 mmol/L

as

serum

potassium

Event and episode of hypokalaemia
Serum potassium <4.4 mmol/L was considered as hypokalaemia. This marked the beginning of an episode of
hypokalaemia. Each potassium replacement was considered an event of hypokalaemia irrespective of whether
hypokalaemia was completely resolved or not. The
episode of hypokalaemia ended when the potassium
level returned to the normal range as described above.
Study setting
The study was conducted in the paediatric cardiac intensive care unit (PCICU) at Aga Khan University Hospital,
Karachi, Pakistan.
Eligibility criteria
Inclusion criteria
This trial included patients, aged 1 month to 15 years,
undergoing surgical repair/palliation of a congenital heart lesion at Aga Khan University Hospital and
admitted to the PCICU for postoperative management.
Patients'/parents' willingness to participate in this study,
serum potassium levels <4.4 mmol/L in the postoperative
period, ability to tolerate oral or nasogastric administration of medication for EPR and presence of a central line
for IVPR were also included in the eligibility criteria.

OBJECTIVES
The primary objective was to compare the equivalence
of efficacy (measured as change in serum potassium
levels in mmol/L and percentage change in level after
potassium replacement) between EPR and IVPR as firstline therapy for the treatment of hypokalaemia. The
secondary objectives were to compare the adverse effects
(hyperkalaemia, diarrhoea, gastrointestinal bleeds,
nausea and vomiting) after EPR and IVPR; to compare
the number of doses required in achieving resolution
of hypokalaemia (as described per protocol) for each
episode; and to determine the efficacy of EPR versus
IVPR for various degrees of severity of hypokalaemia,
that is, mild, moderate or severe.
We hypothesise that EPR will be equally efficacious
in the treatment of hypokalaemia as IVPR, as first-line
therapy.

Exclusion criteria
We excluded patients with acute renal failure (creatinine clearance: ecCr <75%, urine output <0.3 mL/
kg/hour×16 hours).13 Patients with paralytic ileus,
necrotising enterocolitis, gastrointestinal bleeding,
nausea, vomiting or diarrhoea were also excluded as
they could not be given EPR. However, patients were
not excluded if vomiting or diarrhoea developed after
initial recruitment. Patients with critically low serum
potassium <2.0 mmol and patients with symptomatic
hypokalaemia were not recruited.

TRIAL DESIGN
Trial protocol and design have been published previously.12 Briefly, the EIPS trial was designed as a

Study recruitment, procedure and monitoring
A detailed description of recruitment, study procedure and monitoring has been previously published.12

2

Consent procedure
Informed consent and assent was obtained by investigators from each patient (or parents) before cardiac surgery.
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Patients were enrolled and potassium levels were checked
routinely once they were moved to PCICU postoperatively. When the patients developed hypokalaemia, they
received treatment according to the intervention arm
and were followed until they had reached optimal potassium levels or moved from PCICU to a step-down unit.
Repeat serum potassium levels were checked 1 hour
after replacement in the IVPR group and 2 hours after
replacement in the EPR group. Further monitoring of
the serum electrolytes was determined by the patient’s
clinical status.
In cases when the patient stayed in PCICU for longer
than 1 week and block changed, patients continued
to follow the route they were originally assigned. EPR
patients who developed side effects (eg, vomiting,
gastrointestinal upset) or critically low levels of potassium <2 mmol (exclusion criteria) were allowed to cross
over and receive IVPR. An intention to treat analysis was
performed to account for crossover patients.
During the pre-recruitment trial period, it was
recognised that patients who were given enteral potassium supplementation could not tolerate the enteral
formulation and ended up vomiting due to the sour
taste of the formulation. Thus it was decided to administer enteral potassium through a nasogastric (NG)
tube, placed intraoperatively, in mechanically ventilated
patients. Once patients were extubated and started
tolerating oral feeds, enteral potassium supplementation was administered with apple juice to improve the
taste and palatability of the medicine. These measures
were adopted throughout the trial to improve tolerance
and compliance to EPR.
Study drugs, drug management
Drug-dosing protocol for potassium replacement is
shown in table 1; details about the maximum concentration, dose in each arm and drug management can be
reviewed in a previously published protocol.12
Intravenous potassium chloride
The maximum dose was 3 mmol/kg/day. The dilution
and infusion rate was 8 mmol/100 mL, 10 mmol/hour for
a peripheral line; 15 mmol/100 mL, 15 mmol/hour for
a central line.

Table 1 Potassium replacement dosing
Serum potassium level Potassium replacement
(mmol/L)
(intravenous and enteral)
4.0–4.4
3.5–3.9

0.1 mmol/kg/dose
0.3 mmol/kg/dose

3.0–3.4

0.5 mmol/kg/dose

2.5–2.9
2.1–2.4

0.7 mmol/kg/dose
1 mmol/kg/dose and call physician

Oral potassium chloride
The
maximum
dose
was
240 mmol/24 hours.
The maximum per dose was 60 mmol. The concentration
was 13.33 mmol/5 mL.
Adverse events
The adverse effects of potassium supplementation that
were monitored included hyperkalaemia (potassium
levels >5 mmol/L), arrhythmias, diarrhoea, gastrointestinal bleeds and nausea and vomiting, during or within
2 hours of potassium replacement.
The adverse events were monitored and documented
on an hourly basis by PCICU nursing staff and notified to
on-call physicians and the principal investigator.
Sample size calculation
The sample size was calculated using an equivalence
test of mean procedure, considering both interventions
(EPR and IVPR) were of equal efficacy with an SD of
4%. The equivalence limit was assumed to be ±(15%),
using a power of 90% and a level of significance of 5%;
a total of 155 events were required in each arm to reject
the null hypothesis which states that there is no difference in efficacy (change in serum potassium levels) of
IVPR and EPR. The sample size was calculated using
PASS software.
Statistical analysis
The primary objective of the study was to compare the
efficacy of EPR and IVPR as a first-line therapy for the treatment of hypokalaemia. The end points (primary outcome)
used were change in serum potassium levels in mmol/L
and percentage change in serum potassium levels after
each event of potassium replacement by both methods.
Data were analysed using two approaches: intention
to treat (ITT) and actual treatment (AT) received analysis. ITT was considered the primary analysis. The mean
(±SD) was calculated for continuous parametric variables while the median was used to describe continuous
non-parametric variables. Categorical variables are
presented as frequencies. To explore bivariate associations, the independent Student t and Mann-Whitney
U tests were used for parametric and non-parametric
continuous variables respectively, while χ2 was used for
categorical variables. Change in potassium concentration over time was assessed by mixed effects regression
modelling; this incorporated a random intercept trend.
This analytic approach included all participants who had
data available on at least one time point. A hierarchical
model was developed that nests an event within an episode
and patients through random intercept modelling to
adjust for inter-individual and episode-related variation
in change in potassium concentration. The analysis
included linear time effect with main effect of treatment
to examine whether the experimental condition (EPR)
resulted in greater changes in potassium than the control
(IVPR) over time. Age of participants, potassium concentration at beginning of episode, average urine output,
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diuretic dose and inotrope score were incorporated in
the model as confounding factors and the results were
reported as coefficients with 95% CIs. Data were analysed
using STATA version 12 through xtmixed command.
The model building command includes three steps.
As a first step an unconditional model was tested with
episode and event level random intercepts to examine
the variation in outcomes at these levels. In the next
step, a time variable was added with outcome as a fixed
effect and random slope. A likelihood ratio (LR) test
was used to confirm whether the variance of the slope is
significantly different from zero. Time was treated as a
fixed effect when the LR test failed to provide evidence
for this null hypothesis. Finally, outcome adjusted for all
potential covariates significant at a liberal p<0.2 in bivariate analysis were retained if significant at p<0.05. Fit of
the models was assessed through Akaike information
criteria (AIC) and Bayesian information criteria (BIC).
Generally the smaller the statistical value, the better the
model fits the data.
An interim analysis was performed after 155 events
(cumulative in both arms) to ensure protocol compliance and to monitor adverse effects. Analysis did not
reveal any major adverse effects and validated comparable efficacy between the two arms. Thus, no major
changes were made to the protocol and the trial was
continued to achieve the final sample size.
Data collection, storage and record keeping
The data abstraction form was used to abstract patient
data for the study.
Data were collected by investigators (NR, QM, AR)
throughout the duration of the study and were kept safe
under lock and password protected e-files at all times.
Ethics committee and regulatory approval
This study was approved by the ERC and Clinical Trials
Unit at Aga Khan University Hospital.
RESULTS
Patients were recruited from December 2013 to May
2014. Initially 55 patients were approached. The first
10 patients were recruited and consented to participate
in the pre-trial period; they were not included in the
trial analysis. During the pre-trial period, the EPR and
IVPR potassium protocol was introduced for the training
of staff nurses. The next 45 patients were recruited
for the trial. Of these, four were excluded as they did
not meet the inclusion criteria (two participants were
excluded as they developed critically low levels of potassium, while the other two participants did not develop
an episode of hypokalaemia during their PCICU stay).
Thus 41 patients fulfilled the inclusion criteria for the
trial. There was no attrition from the patients recruited.
The most common cardiac lesion in both the groups
was found to be a ventricular septal defect (VSD) and
the most common surgical procedure was VSD closure.
None of the patients received continuous or modified
4

ultrafiltration during or after surgery. After randomisation, 18 patients were recruited to the IVPR arm and
23 patients to the EPR arm. The mean age of patients
was 4.8 (SD ±4) in the IVPR group and 4.6 (SD ±4.0) in
the EPR group (table 2a).
Five patients from the EPR arm crossed over to
the IVPR arm (figure 1) due to development of
adverse events: four vomiting and one arrhythmia.
The median length of PCICU stay was 2 (0.63–14) days
and 1.95 (0.58–8) days (p=0.26) in the IVPR and EPR
arms respectively. The median length of hospital stay
for the IVPR arm was 7 (3–19) days while in the EPR
arm it was 6 (4–18) days (p=0.83). A total of 97 episodes
of hypokalaemia were recorded (48 and 49 in the IVPR
and EPR arms respectively). From these episodes, a total
of 460 events of hypokalaemia were recorded (234 and
226 in the IVPR and EPR arms respectively). There was
no difference in episodes (IVPR 2.7, SD ±2.1; EPR 2.1,
SD ±1.3) and events (number of doses) (IVPR 5.0, SD
±4.9; EPR 4.6, SD ±4.2) per child between the two arms
(table 2b).
Mode of supplementation and response to therapy
There was no difference between IVPR and EPR arms
in the mean serum potassium levels at the beginning
(3.67±0.42 vs 3.62±0.48, p=0.45 respectively) and at
the end of the episode of hypokalaemia (4.47±0.62 vs
4.48±0.60, p=0.94 respectively) (figure 2).
Univariate analysis showed no difference in response
to therapy (number of doses required, absolute change
(intravenous 0.82±0.7; 95% CI 0.62 to 1.01 vs oral 0.86±0.8;
95% CI 0.62 to 1.10; p=0.8) and percentage change (intravenous 24±20; 95% CI 18 to 30 vs oral 26±30; 95% CI 18 to
35; p=0.59) in potassium levels in both arms at the initial
episode (table 2b). The overall difference of relative
change in potassium concentration was −2.7% (95% CI
−12.8% to 7.3%) with ITT analysis which was within the
predetermined equivalence limit (±15%).
Actual treatment received analysis was also performed
and findings were not significantly different from ITT
analysis.
Using repeated measures analysis, after adjusting for the
age of the patient, potassium concentration at the beginning of the episode, average urine output, inotropic score
and diuretic dose, the change in absolute potassium level
for each event of hypokalaemia was equal with no statistically significant difference between the two arms for ITT
(β=0.01; 95% CI −0.08 to 0.10; p=0.86) and actual treatment analysis. Similar results were seen when analysis was
performed using percentage change in potassium levels
after supplementation for ITT (β=0.30; 95% CI −3.42 to
4.03, p=0.87) and actual treatment analysis (table 3, see
online supplementary table 1, table 2, table 3).
Linear mixed effect regression analysis was adjusted
for episode level variations and controlled for covariates
of age, potassium levels at the beginning of the episode,
inotropic score, average urine output and average diuretic
dose. The β coefficient is the standardised coefficient’

Rehman Siddiqu Nur, et al. BMJ Open 2017;7:e011179. doi:10.1136/bmjopen-2016-011179

Downloaded from http://bmjopen.bmj.com/ on March 13, 2018 - Published by group.bmj.com

Open Access
Table 2a Baseline characteristics of enrolled children in IVPR and EPR arms
Intention to treat (ITT)

Actual treatment received(AT)

Intravenous K (n=18) Oral K (n=23) p-value

Intravenous K (n=23) Oral K (n=18) p-value

Age at randomisation
(count, %)
<1 year

5 (27.8%)

4 (17.4%)

6 (26.1%)

3 (16.7%)

1–5 years

5 (27.8%)

10 (43.5%)

7 (30.4%)

8 (44.4%)

5–15 years

8 (44.4%)

9 (39.1%)

10 (43.5%)

7 (38.9%)

Mean age (years)*

4.8±4.0

4.6±4.0

0.91

4.8±4.2

4.6±3.8

0.87

Mild

33 (71.7%)

31 (63.3%)

0.47

41 (74.5%)

23 (57.5%)

0.14

Moderate

13 (28.3%)

17 (34.7%)

14 (25.5%)

16 (40.0%)

Severe

–

1 (2.0%)

–

1 (2.5%)

Mean potassium*

3.7±0.5
(3.5 to 3.8)

3.6±0.5
(3.5 to 3.8)

0.71

3.7±0.5
(3.6 to 3.8)

3.6±0.5
(3.4 to 3.7)

0.23

Average urine output (ml/
kg/hour)*

3.9±2.1
(3.4–4.6)

4.3±2.5
(3.6–5.0)

0.44

4.1±2.2
(3.5–4.7)

4.2±2.5
(3.4–5.0)

0.81

Diuretic average dose
(mg/kg)*‡

0.4±0.5
(0.3–0.6)

0.4±0.6
(0.2–0.5)

0.57

0.5±0.6
(0.3–0.6)

0.3±0.4
(0.2–0.4)

0.15

Inotrope score*

8.5±9.1
(5.5–10.7)
48

4.6±4.1
(3.4–5.8)
49

0.01

8.4±8.8
(5.6–10.5)
57

4.1±3.3
(3.0–5.1)
40

0.004

0.54

0.61

Indicators at beginning of
episode
Potassium level
(count, %)†

Total episodes

*Values reported as mean±SD (95% CI)
†Severity of hypokalaemia defined as potassium level of mild: 3.5–4.4 mEq/L, moderate: 2.5–3.4 mEq/L, severe: 2.1–2.4 mEq/L
‡Diuretics were given either at bolus every 6 hours or as a continuous infusion. Average dose was calculated as total diuretic (mg) received in
6 hours/ weight (kg) of the patient/6 to get mg/kg/hour.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.

Figure 1 Recruitment flow chart EIPS.
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Table 2b Episodes, events and mean percentage change in potassium concentration in the IVPR and EPR arms
Intention to treat (ITT)

Actual treatment received(AT)

Intravenous K Oral K
Events
Episode per child (N)

234
18

226
23

Mean±SD

2.7±2.1

2.1±1.3

p-value*

0.32

Event per episode (N)

48

49

Mean±SD

5.0±4.9

4.6±4.2

Change in potassium (N)†

48

49

Mean±SD
95% CI

0.82±0.7
(0.62 to 1.01)

0.86±0.8
(0.62 to 1.10)

Relative percentage change 48
in potassium (N)‡

0.70
0.80

49
26±30
(18 to 35)

0.59

Intravenous K Oral K
279
23

181
18

2.5±1.9

2.2±1.4

57

40

5.0±4.8

4.5±4.2

57

40

0.78±0.6
(0.65 to 0.95)

0.93±0.8
(0.64 to 1.21)

57

40

22±20
(17 to 27)

29±30
(19 to 39)

Mean±SD
95% CI

24±20
(18 to 30)

Mean difference (95% CI)

−2.7%
(−12.8% to 7.3%)

−5.5%
(−17% to 4.2%)

Relative percentage
change in potassium first
episode (N)‡
Mean±SD
95% CI

18

23

23

18

25±20
(16 to 34)

30±20
(19 to 41)

24±20
(16 to 31)

33±30
(20 to 46)

0.51

p-value*

0.63
0.64
0.34

0.20

0.18

Baseline characteristics of patients in both arms are presented in table 2a. Both groups had similar baseline characteristics; however, the
IVPR arm had a higher inotropic score compared with the EPR arm for ITT (8.5±9.1 vs 4.6±4.1, p=0.01 respectively) and actual treatment
(8.4±8.8 vs 4.1±3.3, p=0.004 respectively) analysis. All values reported as mean±SD (95% CI).
*Mann–Whitney U test was used for comparison of episodes and events due to skewed distribution while change in potassium concentration
and relative percentage change were compared using an independent sample t test.
†Change in potassium concentration calculated as last event K – first event K of an episode.
‡Relative percentage change calculated as (first K value of the episode – last K value of the episode)/first K value of the episode * 100.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.

showing the degree of impact of intervention on the
outcome.
Adverse events
No mortality occurred in either of the arms. A total of five
adverse events were observed in the EPR arm while none
were recorded in the IVPR arm. Out of these five cases, four
were episodes of vomiting within 2 hours of enteral potassium replacement. A single atrial arrhythmia occurred in
a 4.5 month old patient who underwent complete repair
for tetralogy of Fallot. Abnormal rhythm was noticed an
hour after enteral supplementation for treating mild hypokalaemia. Rhythm was evaluated to be a run of ectopic
atrial tachycardia. This patient was also noted to have such
episodes of tachycardia in the immediate postoperative
period before the enteral supplementation was started.
The rhythm improved after the patient was placed on oral
amiodarone. No episodes of hyperkalaemia were appreciated.
DISCUSSION
Our trial portrays comparable efficacy of both the modes
of supplementation, intravenous and enteral, as first-line
therapy for the correction of hypokalaemia in paediatric
6

patients in the PCICU setting post cardiac surgery.
Through this trial we were able to establish that enteral
potassium supplementation is an equally efficacious and
safe mode of potassium replacement as first-line therapy
during hypokalaemia in selected patients with congenital heart disease in the immediate postoperative period.
Paediatric patients, after congenital heart disease
repair, are particularly susceptible to hypokalaemia in
the postoperative period due to administration of high
doses of loop diuretics and inotropes.1 7 In the immediate postoperative period, the body does not conserve
potassium efficiently, thus making potassium supplementation a requirement for many such paediatric patients
after cardiac surgery.1 Potassium supplementation has
a narrow therapeutic range and thus a guarded safety
profile. Although serious adverse effects with either
mode of supplementation are quite rare, inappropriate
administration of potassium in these patients may lead to
worsening of heart failure, cardiac arrest, hyperkalaemia,
arrhythmias and death.2 8 9 Given all the above mentioned
factors, efficient potassium replacement through a safe
route holds pivotal importance in paediatric patients
after cardiac surgery.
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Figure 2 Change in potassium concentration at the beginning and end of episode.

Comparable efficacy between enteral and intravenous
potassium supplementation was initially demonstrated
in a recent retrospective study.9 This retrospective
study conducted by Moffet et al included 66 paediatric
patients post congenital heart surgery who received

399 blouses of potassium (266 intravenous and 233
enteral). As a change of practice was advocated to
encourage the use of enteral potassium supplementation before data collection for this retrospective
study, the authors believe that the physician’s clinical

Table 3 Repeated measure analysis of change in serum potassium concentration in IVPR and EPR arms (ITT)
Unadjusted
Coef.

Adjusted*
SE

95% CI

p-value

Coef.

SE

95% CI

p-value

0.05

−0.08 to
0.13

0.66

0.01

0.05

−0.08 to
0.10

0.86

1.90

−3.42 to
4.03

0.87

1.50

−1.76 to
4.08

0.44

Potassium concentration
Intervention
Oral K

0.02

Intravenous Ref
K

Ref

Percentage change in potassium concentration*
Intervention
Oral K

0.10

1.89

−3.60 to
3.80

0.95

Intravenous Ref
K

0.30
Ref

Percentage change (per hour) in potassium concentration*
Intervention
Oral K

−3.01

1.55

−6.11 to
−0.003

0.05

1.16

Intravenous Ref
K
*Percentage change calculated as (previous K – current K)/previous K * 100.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.
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experience and judgement may have skewed administration of enteral potassium to less critically ill patients.
Also, limitations associated with a retrospective review
reduced the generalisability of findings of this study.
Taking the above-mentioned limitations into consideration, a prospective study with a predefined protocol
and practices in place to reduce clinician to clinician
variability is warranted.
Although equally efficacious in improving potassium
levels, IVPR requires stringent monitoring by PCICU
staff and the presence of a central line.9 Correcting
potassium levels back to normal usually requires multiple
replacements, making repeated access to the central line
a necessity. This may lead to central line related infections.9 14 Also, transition to enteral supplementation from
IVPR poses a challenge in some patients and central lines
have to be kept in place longer than otherwise required
for intravenous potassium supplementation.14 Another
downside of using IVPR is that a large volume of fluid is
required for the delivery of the desired dose of potassium
with peripheral lines which is not preferable in postoperative cardiac patients in whom clinicians aim to achieve
negative fluid balance. However, enteral supplementation with comparable efficacy offers many advantages.
It is easier to transition paediatric patients after surgery
for congenital heart disease directly to enteral supplementation and if required they can be discharged home
on this supplementation. Moreover, use of enteral potassium supplementation can lead to significant reduction
in fluid administration, which is of great advantage as
hypokalaemia is frequently a consequence of administration of loop diuretics to treat fluid overload in these
patients. Although, paediatric data regarding pharmacokinetics of enteral potassium supplementation are
lacking, safety and efficacy of enteral supplementation
of potassium in the adult population has been well
established previously. One more potential advantage
of administrating enteral potassium supplementation
for treatment of hypokalaemia is its cost effectiveness.9
Along with being ten times more costly than EPR at our
institution, IVPR also requires central line utilisation,
increased nursing time and syringe pump utilisation that
further adds to the overall cost of potassium supplementation. Adverse events seen in the enteral arm mainly
comprised episodes of vomiting seen in some participants at the beginning of the trial. This can be attributed
to the sour taste the of formulation or inappropriately
fast administration through the NG tube. The former
can be taken care of by feeding through the NG tube
or mixing the enteral potassium formulation with fruit
juices. Other than these few episodes of vomiting, participants in this trial tolerated enteral supplementation
of potassium well. Given its equal efficacy, low adverse
event profile and a potential benefit, EPR was shown to
be an excellent alternative to IVPR as first-line therapy
in our patient cohort.
8

GENERALISABILITY
EIPS included patients received in the PCICU after
cardiac surgery. The mean age of participants was 4.7
years, with the youngest child being 1 month and the
oldest child being 14 years. The predominant surgical
procedure was VSD repair surgery. We believe that the
results of our study can be generalised to these patient
populations. However, there were only two patients with
severely low potassium levels (see definition) and patients
with critically low potassium, that is <2.0 mmol/L, who
were excluded from the trial, thus the results from this
trial should be generalised with caution in patients with
severely and critically low potassium levels. Further
investigation is warranted to determine the safety profile
of enteral potassium in these patients. Also, EIPS is a
single-centre randomised study, with alternate week
patient randomization, leading to potential significant
selection and allocation bias and limiting generalisability of the findings.
We used a more aggressive potassium replacement
strategy, that is levels between 3.5 and 4.4 mmol/L, based
on observations that higher potassium levels are required
in cardiac patients.7 Though no episode of hyperkalaemia
was noticed in our cohort, our study is not powered to
comment on the safety of this strategy.
LIMITATIONS
EIPS is a single-centre, non-blinded equivalence study
that may lead to observer bias. Blinding was not feasible
in this trial owing to different routes of administration of
the same supplementation (enteral vs intravenous) and
different time interval for checking serum levels in each
arm (1 hour after intravenous replacement and 2 hours
after enteral replacement). Confounding factors, such
as concomitant use of diuretics and inotropic agents
during the episode, may have affected potassium metabolism. These factors were identified and were adjusted
in the analysis.
An auto-analyser, located in PCICU, was used to
measure point of care potassium levels in this trial. This
might have been a potential limiting factor in our study.
Central lab values, although being gold standard, could
not be used as turnover time for each sample at our institution is about 4 hours. Central lab values were obtained
only when a critically low or high value was seen on the
auto-analyser testing. A strong correlation between two
values had previously been established during daily practice at our PCICU.
Difference in severity of the patient’s condition
(as depicted by difference in inotropic scores in the
2 arms) may also have confounded our results. This
was accounted for at a statistical level by adjusting for
inotropic scores in the multivariate modelling and did
not seem to affect the results.
Some participants got moved out of PCICU before
completion of an episode of hypokalaemia. Patients
could not be followed once they moved out of PCICU

Rehman Siddiqu Nur, et al. BMJ Open 2017;7:e011179. doi:10.1136/bmjopen-2016-011179

Downloaded from http://bmjopen.bmj.com/ on March 13, 2018 - Published by group.bmj.com

Open Access
to a step-down unit or floor as stringent monitoring for
trial and point of care potassium levels was not available
in floor settings. This does affect the generalisability of
study. Routinely, patients who get moved to step-down
units or floor receive oral potassium supplementation
in our institution.
It is imperative to know that enteral potassium replacement may not be possible in some patients due to
gastrointestinal intolerance.
Lastly, our trial was also underpowered to detect
difference in frequency of adverse effects between both
arms. This limits inference of equivalence between the
two modes when it comes to their safety/adverse events
profile.

CONCLUSION
We found similar effectiveness of EPR or IVPR, as first-line
therapy, in treating hypokalaemia in paediatric patients
after surgery for congenital heart disease. EPR may be an
equally efficacious alternative to treat hypokalaemia, as
first-line therapy, in these patients.
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